This company has been acquired
Applied Genetic Technologies Future Growth
Future criteria checks 2/6
Key information
6.5%
Earnings growth rate
29.5%
EPS growth rate
Biotechs earnings growth | 20.9% |
Revenue growth rate | 68.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | n/a |
Recent future growth updates
Recent updates
AGTC receives positive feedback from FDA for manufacturing facility
Jul 26Applied Genetic Technologies proposes stock offering to fund clinical trials
Jul 12Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022
Jan 12An Assessment Of Applied Genetic Technologies Corporation
Dec 14Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk
Jul 15Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?
May 21Applied Genetic trades lower after announcing the departure of chief scientific officer
Apr 26What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?
Feb 05Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?
Jan 06What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Dec 11Interim data on gene therapy for vision loss disorder fails to lift Applied Genetic
Nov 11Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2025 | 12 | -100 | -127 | -99 | 2 |
6/30/2024 | N/A | -90 | -110 | -93 | 3 |
6/30/2023 | 0 | -78 | -96 | -87 | 5 |
9/30/2022 | 0 | -70 | -68 | -66 | N/A |
6/30/2022 | 0 | -69 | -68 | -66 | N/A |
3/31/2022 | 1 | -63 | -63 | -61 | N/A |
12/31/2021 | 1 | -63 | -60 | -58 | N/A |
9/30/2021 | 1 | -60 | -56 | -54 | N/A |
6/30/2021 | 1 | -58 | -53 | -51 | N/A |
3/31/2021 | N/A | -60 | -53 | -52 | N/A |
12/31/2020 | N/A | -57 | -50 | -49 | N/A |
9/30/2020 | 2 | -50 | -45 | -44 | N/A |
6/30/2020 | 2 | -46 | -43 | -42 | N/A |
3/31/2020 | 3 | -42 | -37 | -35 | N/A |
12/31/2019 | 24 | -19 | -34 | -34 | N/A |
9/30/2019 | 28 | -15 | -35 | -35 | N/A |
6/30/2019 | 42 | -2 | -24 | -23 | N/A |
3/31/2019 | 47 | 2 | -23 | -23 | N/A |
12/31/2018 | 29 | -18 | -24 | -23 | N/A |
9/30/2018 | 28 | -19 | -24 | -23 | N/A |
6/30/2018 | 24 | -21 | -33 | -33 | N/A |
3/31/2018 | 27 | -18 | -37 | -36 | N/A |
12/31/2017 | 32 | -11 | -37 | -37 | N/A |
9/30/2017 | 38 | -4 | -35 | -34 | N/A |
6/30/2017 | 39 | 0 | -32 | -31 | N/A |
3/31/2017 | 43 | 6 | -29 | -28 | N/A |
12/31/2016 | 47 | 10 | -31 | -28 | N/A |
9/30/2016 | 48 | 11 | -32 | -30 | N/A |
6/30/2016 | 47 | -1 | N/A | 71 | N/A |
3/31/2016 | 36 | -12 | N/A | 72 | N/A |
12/31/2015 | 24 | -20 | N/A | 75 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: AGTC is forecast to remain unprofitable over the next 3 years.
Beneficios frente mercado: AGTC is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: AGTC is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: AGTC's revenue (68% per year) is forecast to grow faster than the US market (7% per year).
Ingresos de alto crecimiento: AGTC's revenue (68% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): Insufficient data to determine if AGTC's Return on Equity is forecast to be high in 3 years time